Elutia Seeks FDA Clearance for NXT-41 in H2 2026 with $44.4M Cash
Elutia ended 2025 with $44.4 million in cash and escrow after repaying $26.9 million in debt and closing an $88 million BioEnvelope divestiture to Boston Scientific. It submitted its NXT-41 510(k) application to FDA, targeting clearance in H2 2026 and full NXT-41x approval by H1 2027.
1. NXT-41 Regulatory Milestones
Elutia has submitted the 510(k) application for its base biologic matrix NXT-41 to the FDA, with clearance anticipated in the second half of 2026. Full approval of the drug-eluting NXT-41x platform is expected in the first half of 2027, targeting a $1.5 billion U.S. breast cancer surgery market where infection rates range between 15% and 20%.
2. Financial Position and BioEnvelope Divestiture
The company closed the $88 million sale of its EluPro™ and CanGaroo BioEnvelope business on October 1, 2025, and holds $36.4 million in cash plus $8.0 million in escrow as of year-end. During Q4 2025, Elutia repaid $26.9 million in outstanding debt and related fees, transforming its balance sheet and extending its cash runway.
3. Leadership and Commercial Readiness
Elutia strengthened its commercial leadership with the additions of Guido J. Neels to the Board and Pete Ligotti as Chief Commercial Officer. These appointments support launch readiness and commercialization strategy for the NXT-41x platform.
4. Q4 and Full Year 2025 Results
Continuing operations delivered net sales of $3.3 million in Q4 2025, up 16% year-over-year, driven by cardiovascular sales rising from $0.5 million to $1.2 million. GAAP gross margin improved to 58.5%, operating expenses were $8.5 million, and net loss from continuing operations narrowed to $6.5 million, while discontinued operations drove total net income of $70.8 million.